Leukemia

Recruiting

A Study of Pirtobrutinib in Participants with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

J2N-OX-JZNN - ClinicalTrials.gov - NCT04666038

This is a study for participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already received treatment. The main purpose is to compare pirtobrutinib to other drugs that have already been approved by the United States Food and Drug Administration (US FDA) for CLL/SLL.
How long will I be in the trial?
Participation could last up to four years, and possibly longer, if the disease does not progress.
Email
Recruiting

A Study of Pirtobrutinib in Participants with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

J2N-OX-JZNN - ClinicalTrials.gov - NCT04666038

This is a study for participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already received treatment. The main purpose is to compare pirtobrutinib to other drugs that have already been approved by the United States Food and Drug Administration (US FDA) for CLL/SLL.
How long will I be in the trial?
Participation could last up to four years, and possibly longer, if the disease does not progress.
Email

Key Requirements

Age :

18+

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Have chronic lymphocytic leukemia or small lymphocytic lymphoma that requires treatment

Have received prior treatment, including with a type of medicine called a BTK inhibitor

Be well enough to perform their own personal care

Have adequate organ function and blood counts, as measured by blood tests

Participants must NOT

Have cancer that has become very aggressive or has spread to the brain or spinal cord

Have serious heart disease

Need a blood thinner called warfarin

Have any problems absorbing food or medicine taken by mouth

Take certain medicines that affect how fast the study drug is broken down in the body

Have active infection

Trial Summary

Conditions the trial is for

Leukemia, Lymphoma

What the trial is testing?

Pirtobrutinib (LOXO-305), Idelalisib plus Rituximab (IdelaR), Bendamustine plus Rituximab (BR)

Could I receive a Placebo?

no

Enrollment Goal

250

Trial Dates

March 2021 - July 2023

Trial Phase

3

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Have chronic lymphocytic leukemia or small lymphocytic lymphoma that requires treatment

Have received prior treatment, including with a type of medicine called a BTK inhibitor

Be well enough to perform their own personal care

Have adequate organ function and blood counts, as measured by blood tests

Participants must NOT

Have cancer that has become very aggressive or has spread to the brain or spinal cord

Have serious heart disease

Need a blood thinner called warfarin

Have any problems absorbing food or medicine taken by mouth

Take certain medicines that affect how fast the study drug is broken down in the body

Have active infection

Trial Summary

Conditions the trial is for

Leukemia, Lymphoma

What the trial is testing?

Pirtobrutinib (LOXO-305), Idelalisib plus Rituximab (IdelaR), Bendamustine plus Rituximab (BR)

Could I receive a Placebo?

no

Enrollment Goal

250

Trial Dates

March 2021 - July 2023

Trial Phase

3

Trial Locations

Hide locations not currently recruiting